Who are Placebo matched to VX-661/ ivacaftor's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ivacaftor+lumacaftor, LUM/IVA, Lumacaftor plus Ivacaftor.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-matched-to-vx-661-ivacaftor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Placebo matched to VX-661/ ivacaftor — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo matched to VX-661/ ivacaftor (Placebo matched to VX-661/ ivacaftor) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CFTR modulator combination (corrector + potentiator). Area: Pulmonary / Genetic Disorders.

phase 3 CFTR modulator combination (corrector + potentiator) CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Pulmonary / Genetic Disorders Small molecule Live · refreshed every 30 min

Target snapshot

Placebo matched to VX-661/ ivacaftor (Placebo matched to VX-661/ ivacaftor) — Vertex Pharmaceuticals Incorporated. This is a placebo control arm in a clinical trial comparing VX-661 (a CFTR corrector) combined with ivacaftor (a CFTR potentiator) against placebo in cystic fibrosis patients.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo matched to VX-661/ ivacaftor TARGET	Placebo matched to VX-661/ ivacaftor	Vertex Pharmaceuticals Incorporated	phase 3	CFTR modulator combination (corrector + potentiator)	CFTR (Cystic Fibrosis Transmembrane Conductance Regulator)
Ivacaftor+lumacaftor	Ivacaftor+lumacaftor	Assistance Publique - Hôpitaux de Paris	marketed	CFTR modulator combination (corrector + potentiator)	CFTR (cystic fibrosis transmembrane conductance regulator)
LUM/IVA	LUM/IVA	Vertex Pharmaceuticals Incorporated	marketed	CFTR modulator combination (corrector + potentiator)	CFTR (cystic fibrosis transmembrane conductance regulator)
Lumacaftor plus Ivacaftor	Lumacaftor plus Ivacaftor	Hannover Medical School	phase 3	CFTR modulator combination (corrector + potentiator)	CFTR (cystic fibrosis transmembrane conductance regulator)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CFTR modulator combination (corrector + potentiator) class)

Vertex Pharmaceuticals Incorporated · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Hannover Medical School · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo matched to VX-661/ ivacaftor — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-matched-to-vx-661-ivacaftor. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab